Obesity
Drug Dosing: Obese Patients
Overview of Fatty Acid Metabolism
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Liver Histology
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 27, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Manuela Merli1, Barbara Lattanzi, Francesca Aprile
1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Sarcopenic obesity, characterized by low muscle mass and excess fat, is an independent risk factor for developing nonalcoholic fatty liver disease (NAFLD). This condition is also linked to more severe liver fibrosis in patients with NAFLD.
11:08The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
Published on: March 13, 2014
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: